Leerink Partnrs Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold

Century Therapeutics (NASDAQ:IPSC) was downgraded by investment analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other equities research analysts have also issued reports on IPSC. Leerink Partners restated a “market perform” rating and issued a $2.00 target price (down previously from $7.00) on shares of Century Therapeutics in a research note on Monday. Wall Street Zen lowered Century Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.40.

Century Therapeutics Trading Up 2.0%

Shares of Century Therapeutics stock opened at $0.49 on Monday. Century Therapeutics has a twelve month low of $0.34 and a twelve month high of $1.83. The stock has a market cap of $42.78 million, a price-to-earnings ratio of -1.53 and a beta of 1.80. The company has a fifty day moving average price of $0.54 and a 200 day moving average price of $0.55.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. Analysts forecast that Century Therapeutics will post -1.61 earnings per share for the current year.

Hedge Funds Weigh In On Century Therapeutics

Large investors have recently made changes to their positions in the business. Prudential Financial Inc. acquired a new position in shares of Century Therapeutics in the 2nd quarter worth approximately $25,000. Qube Research & Technologies Ltd acquired a new position in Century Therapeutics in the second quarter worth approximately $38,000. Y Intercept Hong Kong Ltd bought a new position in shares of Century Therapeutics in the second quarter valued at $50,000. Raymond James Financial Inc. bought a new position in shares of Century Therapeutics in the second quarter valued at $51,000. Finally, AQR Capital Management LLC lifted its position in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after acquiring an additional 86,875 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.